Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11371
Peer-review started: August 1, 2022
First decision: August 22, 2022
Revised: August 30, 2022
Accepted: September 23, 2022
Article in press: September 23, 2022
Published online: November 6, 2022
Processing time: 86 Days and 14 Hours
Tenofovir disoproxil fumarate (TDF) is recommended as one of the first-line antiviral agents. The effects of TDF on lipid profiles in patients with chronic hepatitis B (CHB) and overweight are largely unknown.
Overweight is a global pandemic associated with dyslipidemia. Correlation between triglyceride (TG) and estimated glomerular filtration rate (eGFR) remains largely unclear.
To determine the impact of 3-year TDF treatment on lipid metabolism profiles and renal function in Chinese patients with CHB and overweight.
This multi-centre, retrospective cohort study included CHB patients who received TDF treatment. According to the body mass index (BMI) at the initiation of TDF treatment, CHB patients were divided into different groups. Changes of lipid profiles and renal function, as well as the risk factors for eGFR < 90 mL/(min·1.73 m2) were analyzed. Spearman correlation was used to analyze the correlation between eGFR and lipid profiles.
In non-overweight patients, TG was negatively correlated with GFR at the four-time points (P = 0.002, 0.030, 0.007, 0.008, respectively).
There is a negative relation between TG and changes in eGFR during TDF treatment in patients with CHB and normal BMI.
TG regulation may be beneficial for reducing the renal toxicity of TDF.